Cancer Research AACR Legacy Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 107-114, January 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milas, L.
Right arrow Articles by Hittelman, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milas, L.
Right arrow Articles by Hittelman, W.
[Cancer Research 59, 107-114, January 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Enhancement of Tumor Radioresponse in Vivo by Gemcitabine1

Luka Milas2, Takashi Fujii3, Nancy Hunter, Mohamed Elshaikh4, Kathy Mason, William Plunkett, K. Kian Ang and Walter Hittelman

Departments of Experimental Radiation Oncology [L. M., T. F., N. H., M. E., K. M.], Clinical Investigation [W. P., W. H.], and Radiation Oncology [K. K. A.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Gemcitabine, 2'2'-difluoro-2'-deoxycytidine, is an inhibitor of DNA synthesis and has been shown previously in vitro and in vivo to enhance the cytotoxic activity of radiation as well as some chemotherapeutic agents. Because gemcitabine has shown clinical activity on its own in several solid tumors traditionally treated with radiotherapy, it was of interest to optimize the combination of gemcitabine and radiation. To determine the optimal gemcitabine dose to combine with irradiation and to determine the effect of gemcitabine on tumor growth, mice bearing SA-NH tumors were treated with 2.5 to 600 mg/kg gemcitabine, and subsequent tumor growth was determined. At low doses, gemcitabine induced transient growth delay, whereas higher doses showed both cytotoxic and cytostatic activity. Flow cytometric, histological, and mitotic analyses of irradiated tumors showed that gemcitabine induced a dose-dependent inhibition of DNA synthesis and induction of apoptosis of cells in S phase. DNA synthesis recovered in cells at the G1-S boundary of the cell cycle in a dose-dependent manner, and a parasynchronous movement of cells through the cell cycle ensued. To determine the optimal schedule for gemcitabine administration in relation to irradiation, tumor-bearing mice were given a single 50 mg/kg dose of gemcitabine at various times before or after irradiation. Gemcitabine enhanced radioresponse in a time-dependent fashion. The highest enhancement factors for tumor growth delay (1.68–2.03) were observed when gemcitabine was administered 24–60 h before irradiation. Although gemcitabine reduced the radiation tumor control dose at all administration times used, the greatest enhancement of tumor radiocurability occurred when gemcitabine was administered 24 h before irradiation (dose modification factor of 1.54). Moreover, gemcitabine decreased the lung metastatic rate in mice with local tumor control from 73% in mice receiving radiation alone to 40% in mice receiving the combination (all combination times included). These results suggest that gemcitabine has strong radioenhancing properties and that the greatest interaction occurs when gemcitabine administration precedes irradiation by 24–72 h. Preliminary studies indicate that normal tissues recover more quickly than tumor tissues from gemcitabine treatment; thus, optimized scheduling of gemcitabine and irradiation may serve to improve the therapeutic ratio of the combination.




This article has been cited by other articles:


Home page
 JNMHome page
H. Karacay, R. M. Sharkey, D. V. Gold, D. R. Ragland, W. J. McBride, E. A. Rossi, C.-H. Chang, and D. M. Goldenberg
Pretargeted Radioimmunotherapy of Pancreatic Cancer Xenografts: TF10-90Y-IMP-288 Alone and Combined with Gemcitabine
J. Nucl. Med., December 1, 2009; 50(12): 2008 - 2016.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Marechal, J. R. Mackey, R. Lai, P. Demetter, M. Peeters, M. Polus, C. E. Cass, J. Young, I. Salmon, J. Deviere, et al.
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
Clin. Cancer Res., April 15, 2009; 15(8): 2913 - 2919.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, J. Maybaum, and T. S. Lawrence
Improving Gemcitabine-Mediated Radiosensitization Using Molecularly Targeted Therapy: A Review
Clin. Cancer Res., November 1, 2008; 14(21): 6744 - 6750.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Spalding, R. Watson, M. E. Davis, A. C. Kim, T. S. Lawrence, and E. Ben-Josef
Inhibition of Protein Kinase C{beta} by Enzastaurin Enhances Radiation Cytotoxicity in Pancreatic Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6827 - 6833.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Al-Ejeh, J. M. Darby, K. Pensa, K. R. Diener, J. D. Hayball, and M. P. Brown
In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen
Clin. Cancer Res., September 15, 2007; 13(18): 5519s - 5527s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Shewach and T. S. Lawrence
Antimetabolite Radiosensitizers
J. Clin. Oncol., September 10, 2007; 25(26): 4043 - 4050.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, A. Abdulla, J. Flynn, and M. W. Brechbiel
Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease
Clin. Cancer Res., March 15, 2007; 13(6): 1926 - 1935.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F Mornex and N Girard
Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art
Ann. Onc., December 1, 2006; 17(12): 1743 - 1747.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. R. Cardenes, E. G. Chiorean, J. DeWitt, M. Schmidt, and P. Loehrer
Locally advanced pancreatic cancer: current therapeutic approach.
Oncologist, June 1, 2006; 11(6): 612 - 623.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken
Combined Modality Therapy of Gemcitabine and Radiation
Oncologist, January 1, 2005; 10(1): 34 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. A. Huxham, A. H. Kyle, J. H. E. Baker, L. K. Nykilchuk, and A. I. Minchinton
Microregional Effects of Gemcitabine in HCT-116 Xenografts
Cancer Res., September 15, 2004; 64(18): 6537 - 6541.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. W. Robinson, M. M. Im, M. Ljungman, F. Praz, and D. S. Shewach
Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells
Cancer Res., October 15, 2003; 63(20): 6935 - 6941.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. J. Zarba, A. V. Jaremtchuk, P. Gonzalez Jazey, M. Keropian, R. Castagnino, C. Mina, and G. Arroyo
A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma
Ann. Onc., August 1, 2003; 14(8): 1285 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen
A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. A. Wolff, D. B. Evans, D. M. Gravel, R. Lenzi, P. W. T. Pisters, J. E. Lee, N. A. Janjan, C. Charnsangavej, and J. L. Abbruzzese
Phase I Trial of Gemcitabine Combined with Radiation for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Clin. Cancer Res., August 1, 2001; 7(8): 2246 - 2253.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Eisbruch, D. S. Shewach, C. R. Bradford, J. F. Littles, T. N. Teknos, D. B. Chepeha, L. J. Marentette, J. E. Terrell, N. D. Hogikyan, L. A. Dawson, et al.
Radiation Concurrent With Gemcitabine for Locally Advanced Head and Neck Cancer: A Phase I Trial and Intracellular Drug Incorporation Study
J. Clin. Oncol., February 1, 2001; 19(3): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. W. G. van Putten, H. J. M. Groen, K. Smid, G. J. Peters, and H. H. Kampinga
End-joining Deficiency and Radiosensitization Induced by Gemcitabine
Cancer Res., February 1, 2001; 61(4): 1585 - 1591.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
B. A. Teicher, V. Chen, C. Shih, K. Menon, P. A. Forler, V. G. Phares, and T. Amsrud
Treatment Regimens Including the Multitargeted Antifolate LY231514 in Human Tumor Xenografts
Clin. Cancer Res., March 1, 2000; 6(3): 1016 - 1023.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.